Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up ...
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic ...
Ambrose Healthcare’s acquisition of AM-Pharma, valued at up to €161 million plus royalties, strengthens its rare disease pipeline and establishe...
Blackstone Life Sciences (“BXLS”) announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the developm...
Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon a...
OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic tests and sample management solutions, announced that it has joined the Wo...
Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Merck&rsq...
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrat...
Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...
SOTERIA Precision Medicine Foundation (SOTERIA), a California-based 501(c)(3) nonprofit, announces Cancer Hunt™, a nationwide precision oncology prog...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered ...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Or...
© 2026 Biopharma Boardroom. All Rights Reserved.
